Table 2.

Subsets of EPC and EC from viable PBMC isolated from human blood (n=8) (Mean ± SEM). Data are expressed as percent of subsets per number live PBMC from the fresh samples and after cryopreservation for 7 days at −80°C (Gibco and the custom freezing medium). NS using Kruskall-Wallis test.

PBMC phenotype	Proposed Function	Fresh Sample	Cryopreserved with Gibco medium	Cryopreserved with the custom medium	Kruskall-Wallis Statistics
CD34+CD133+VEGFR2−	“Early EPC”	0.3 ± 0.07	0.3 ± 0.1	0.3 ± 0.2	P<0.96
CD34+CD133+VEGFR2+	“Early EPC”	0.2 ± 0.06	0.09 ± 0.05	0.00 ± 0.00	P<0.17
CD34+CD133−VEGFR2+	“Early EPC”	0.6 ± 0.1	0.5 ± 0.2	0.2 ± 0.02	P<0.21
CD146+CD34+VEGFR2−	“Late EPC”	1.1 ± 0.2	1.4 ± 0.4	1.6 ± 0.6	P<0.67
CD146+CD34+VEGFR2+	“Late EPC”	0.6 ± 0.1	0.4 ± 0.2	0.3 ± 0.1	P<0.26
CD146+CD34−VEGFR2+	“EC”	0.8 ± 0.3	0.6 ± 0.1	0.2 ± 0.1	P<0.07